News for Mersana Therapeutics, Inc. (MRSN)

Mersana Therapeutics (MRSN) has shared new interim data from its Phase 1 trial of emiltatug ledadotin, a B7-H4-focused Dolasynthen ADC. This update was delivere

31% confirmed ORR (8 responses in 26 evaluable patients) across B7-H4 high tumors at intermediate doses 44% confirmed ORR (7 responses in 16 evaluable patients)

Operator: Good morning, and welcome to Mersana Therapeutics First Quarter 2025 Conference Call. Currently all participants are in a listen-only mode.

Cash and Cash Equivalents: $102.3 million at the end of Q1 2025.Net Cash Used in Operating Activities: $29.3 million for Q1 2025.Collaboration Revenue: $2.8 mi

May 15, 2025 / 12:00PM GMTOperator Good morning and welcome to the Mersana Therapeutics first-quarter 2025 conference call. (Operator Instructions) I would now

In a release issued under the same headline earlier today by Mersana Therapeutics, Inc. ( MRSN), please note that there was a transcription error in the last ce

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2025 Earnings Conference Call May 15, 2025 8:00 AM ETCompany ParticipantsJason Fredette - Senior Vice President,...

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 9.52% and 62.78%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Mersana Therapeutics (MRSN) Q1 earnings release is set for May 15.

Mersana Therapeutics Inc (MRSN) is set to release its Q1 2025 earnings on May 15, 2025. The consensus estimate for Q1 2025 revenue is $5.84 million, and the ear

PR NewswireAUSTIN, Texas, May 8, 2025 Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna SethAUSTIN, Texas, May 8, 2025 /P

Cost-saving initiatives expected to extend company's cash runway and support current operating plan commitments into mid-2026 Company to host conference call a

**media[582714]**

Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2024 Conference Call. Currently all participants are in a listen-only mode.

Cash, Cash Equivalents, and Marketable Securities: $134.6 million at the end of 2024.Net Cash Used in Operating Activities: $19.3 million for Q4 2024, down fro

Mersana Therapeutics, Inc. Q4 2024 Earnings Conference Call March 3, 2025 8:00 AM ETCompany ParticipantsJason Fredette - SVP, IRMartin Huber - President...

Mersana Therapeutics (MRSN) delivered earnings and revenue surprises of 31.25% and 154.92%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-LeInitiated first expansion cohort in patients with triple-neg

Revenue: Reported $7.68 million for the fourth quarter, meeting the estimated revenue of $7.68 million.Earnings Per Share (EPS): Reported EPS of -$0.15, meetin